Based on four independent clinical materials, reduced levels of nuclear-localized Stat5a were prognostic of unfavorable breast cancer outcome in patients who did not receive systemic adjuvant therapy and were associated with elevated risk of failure of antiestrogen therapy in patients. This evidence concerns the gene STAT5A and breast cancer.